Vamil Divan
Stock Analyst at Guggenheim
(4.85)
# 70
Out of 5,128 analysts
244
Total ratings
68.18%
Success rate
22.27%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $230 → $221 | $176.00 | +25.57% | 8 | Dec 18, 2025 | |
| JNJ Johnson & Johnson | Maintains: Buy | $206 → $227 | $207.49 | +9.40% | 18 | Dec 5, 2025 | |
| PFE Pfizer | Maintains: Buy | $33 → $35 | $25.28 | +38.45% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $13.19 | +28.93% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $1.71 | +367.84% | 1 | Nov 18, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $114 → $115 | $79.47 | +44.71% | 13 | Nov 10, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.64 | +367.95% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $233.42 | +3.68% | 28 | Oct 20, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $5.77 | +90.64% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $9.89 | +31.45% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $31.39 | +24.24% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.42 | +189.26% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $288 | $341.64 | -15.70% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $6.01 | +898.34% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $108.60 | +5.89% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $36.28 | +29.55% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.02 | +148.76% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $48.68 | +25.31% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $18.56 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $4.32 | +501.85% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.41 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $27.42 | -30.71% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $140.62 | -30.31% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $29.36 | +15.80% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.14 | +367.29% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $170.69 | -71.29% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,108.09 | -67.87% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $7.21 | -16.78% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $11.74 | +1,211.75% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $5.66 | +165.02% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.01 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $32.40 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $7.10 | +111.27% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $56.72 | +7.55% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.84 | +2,582.29% | 3 | Jan 17, 2018 |
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $176.00
Upside: +25.57%
Johnson & Johnson
Dec 5, 2025
Maintains: Buy
Price Target: $206 → $227
Current: $207.49
Upside: +9.40%
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $25.28
Upside: +38.45%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $13.19
Upside: +28.93%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.71
Upside: +367.84%
ANI Pharmaceuticals
Nov 10, 2025
Maintains: Buy
Price Target: $114 → $115
Current: $79.47
Upside: +44.71%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.64
Upside: +367.95%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $233.42
Upside: +3.68%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.77
Upside: +90.64%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $9.89
Upside: +31.45%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $31.39
Upside: +24.24%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.42
Upside: +189.26%
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $341.64
Upside: -15.70%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $6.01
Upside: +898.34%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $108.60
Upside: +5.89%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $36.28
Upside: +29.55%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $4.02
Upside: +148.76%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $48.68
Upside: +25.31%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $18.56
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $4.32
Upside: +501.85%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $2.41
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $27.42
Upside: -30.71%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $140.62
Upside: -30.31%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $29.36
Upside: +15.80%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.14
Upside: +367.29%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $170.69
Upside: -71.29%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,108.09
Upside: -67.87%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $7.21
Upside: -16.78%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $11.74
Upside: +1,211.75%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $5.66
Upside: +165.02%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $33.01
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $32.40
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $7.10
Upside: +111.27%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $56.72
Upside: +7.55%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.84
Upside: +2,582.29%